Across TCGA pan-cancer cohorts, PSMB11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSMB11 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PSMB11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMB11 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
CESC, LUAD, and LUSC are the cancer types where PSMB11 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.